Trial intelligence / Profile preview

Phase 3 study of ripretinib versus placebo in advanced gastrointestinal stromal tumor after prior tyrosine kinase inhibitors

NL-OMON50251Phase 3Completed

Sponsor

Deciphera Pharmaceuticals

Start

Sep 2018

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1